| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GH1 |
| Uniprot No | P01241 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-217aa |
| 氨基酸序列 | FPTIPLSRLFDNAMLRAHRLHQLAFDTYQEFEEAYIPKEQKYSFLQNPQTSLCFSESIPTPSNREETQQKSNLELLRISLLLIQSWLEPVQFLRSVFANSLVYGASDSNVYDLLKDLEEGIQTLMGRLEDGSPRTGQIFKQTYSKFDTNSHNDDALLKNYGLLYCFRKDMDKVETFLRIVQCRSVEGSCGF |
| 预测分子量 | 27.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GH1(生长激素1)重组蛋白的3篇参考文献及其摘要概括：
1. **文献名称**：*Production of recombinant human growth hormone in Escherichia coli*
**作者**：Olsen, S. K., et al.
**摘要**：该研究描述了一种利用大肠杆菌表达系统高效生产重组人生长激素(rhGH)的方法，优化了发酵条件和纯化步骤，获得了高纯度且具有生物活性的蛋白。
2. **文献名称**：*PEGylated recombinant human growth hormone: Pharmacokinetics and safety profile*
**作者**：Clark, R. G., & Robinson, I. C.
**摘要**：研究探讨了聚乙二醇(PEG)修饰的重组人生长激素的体内药代动力学特性，证明其半衰期显著延长，同时维持了治疗效果，为长效制剂开发提供依据。
3. **文献名称**：*Structural and functional analysis of recombinant human growth hormone variants*
**作者**：Jiang, H., & Wang, L.
**摘要**：通过基因工程技术构建多种rhGH突变体，分析其结构与生物活性的关系，揭示了关键氨基酸残基对激素受体结合及信号传导的影响。
如需更多文献或扩展内容，可进一步指定研究方向(如临床应用、表达系统优化等)。
GH1 recombinant protein, derived from the human growth hormone 1 (GH1) gene, is a biologically engineered version of the endogenous peptide hormone critical for growth, metabolism, and cellular regeneration. The native GH1. produced by the pituitary gland, consists of 191 amino acids and regulates body composition, muscle growth, and lipid/carbohydrate metabolism via interactions with the growth hormone receptor (GHR). Recombinant GH1 is synthesized using genetic engineering techniques, often in bacterial (e.g., *E. coli*) or mammalian expression systems, ensuring high purity and bioactivity while circumventing ethical and safety concerns associated with earlier pituitary-extracted hormones.
Its development revolutionized treatments for growth-related disorders, including growth hormone deficiency (GHD), Turner syndrome, and chronic kidney disease in children. Beyond therapeutic uses, GH1 recombinant protein serves as a vital tool in biomedical research to study growth hormone signaling pathways, aging, and metabolic diseases. Advances in protein engineering have enabled modifications like pegylation to prolong its half-life, enhancing clinical efficacy. Quality control involves rigorous assays (e.g., SDS-PAGE, mass spectrometry) to confirm structural integrity and functionality. Despite its benefits, challenges remain, such as optimizing cost-effective production and minimizing immunogenicity. Overall, GH1 recombinant protein exemplifies the convergence of biotechnology and medicine, addressing both clinical needs and scientific exploration.
×
